The tumor inhibition rate of 609-Fab-PD-L1-IgG4 in NSG mice bearing an NCI-H292 tumor was 96.0% which was much higher than those of nivolumab (50.5%) and atezolizumab (84.4%). This evidence concerns the gene CD274 and neoplasm.